M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112807 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Wenhua Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shihezi University School of Medicine, Shihezi 832000, China; Key Laboratory for Prevention and Treatment of High Morbidity in Central Asia, National…. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Exosomes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China, Xinjiang Production and Construction Corps Xinjiang Production and Construction Corps.
Abstract (Originalsprache)
OBJECTIVE: Sorafenib is a chemotherapeutic agent used to treat hepatocellular carcinoma (HCC). However, its clinical response rates are often low. Tumour-associated macrophages (TAMs) have been implicated in tumour resistance. The relationship between TAMs-derived exosomes and primary resistance to sorafenib in hepatocellular carcinoma is unclear. METHODS: The study analysed RNA-SEQ data from TCGA-LIHC to explore the relationship between TAMs and sorafenib IC50. THP-1-induced M2 macrophages were used as a model to investigate the relationship between M2 macrophage exosomes and primary resistance to sorafenib in hepatocellular carcinoma cells using apoptosis, colony generation, cell viability and dual luciferase. RESULTS: M2 macrophage score and sorafenib IC50 were positively correlated in hepatocellular carcinoma patients, M2 macrophage exosomes promoted sorafenib resistance in hepatocellular carcinoma cells, and M2-exo-miR-200c-3p facilitated the development of sorafenib resistance in hepatocellular carcinoma cells by mediating the activation of PI3K/AKT. CONCLUSION: We propose and demonstrate for the first time that M2 macrophage exosomes promote sorafenib resistance in hepatocellular carcinoma, providing a new perspective for the clinical treatment of hepatocellular carcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shihezi University School of Medicine, Shihezi 832000, China; Key Laboratory for Prevention and Treatment of High Morbidity in Central Asia, National Health and Health Commission, Shihezi 832000, China.
- Shihezi University School of Medicine, Shihezi 832000, China; The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832000, China; Key Laboratory for Prevention and Treatment of High Morbidity in…
- Shihezi University School of Medicine, Shihezi 832000, China; Key Laboratory for Prevention and Treatment of High Morbidity in Central Asia, National Health and Health Commission, Shihezi 832000, China. Electronic addre…
Förderung
- Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China
- Xinjiang Production and Construction Corps Xinjiang Production and Construction Corps
Zitieren
APA
Li, W., Zhao, B., Wang, Q., Lu, J., Wu, X., & Chen, X. (2024). M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112807
Vancouver
Li W, Zhao B, Wang Q, Lu J, Wu X, Chen X. M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112807
BibTeX
@article{Li2024,
author = {Li, Wenhua and Zhao, Bin and Wang, Qianwen and Lu, Junxia and Wu, Xiangwei and Chen, Xueling},
title = {M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112807}
}
EUVIMED